Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15001031 | 0.82 | PNMT (0.43) | PNMTNOS3NOS2ALDH1A1MEN1 | |
| SCHEMBL12711268 | 0.78 | NOS3 (0.35) | PNMTNOS3NOS2 | |
| SCHEMBL1822840 | 0.77 | PNMT (0.39) | PNMTALDH1A1MEN1TSHRCYP2C19 | |
| SCHEMBL19122298 | 0.77 | — | — | |
| SCHEMBL13183593 | 0.77 | PNMT (0.48) | PNMTNOS3NOS2ALDH1A1MEN1 | |
| SCHEMBL1823806 | 0.77 | NOS3 (0.39) | PNMTNOS3NOS2ALDH1A1 | |
| SCHEMBL17339839 | 0.75 | NOTUM (0.36) | PNMTNOS3NOS2ALDH1A1TSHR | |
| SCHEMBL10356895 | 0.73 | NOS3 (0.33) | PNMTNOS3NOS2 | |
| SCHEMBL17339851 | 0.73 | PNMT (0.50) | PNMTNOS3NOS2MEN1TSHR | |
| SCHEMBL15274308 | 0.72 | NOS3 (0.32) | PNMTNOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130144065-A1 | SEMICONDUCTOR MATERIALS PREPARED FROM BRIDGED BITHIAZOLE COPOLYMERS | POLYERA CORPORATION (US) | 2013-06-06 | — | — | US | disclosed |
| US-7635781-B2 | Synthesis of cyclopentadiene derivatives | BASELL POLYOLEFINE GMBH (DE) | 2009-12-22 | — | — | US | disclosed |
| US-20080287692-A1 | Synthesis of cyclopentadiene derivatives | BASELL POLYOLEFINE GMBH (DE) | 2008-11-20 | — | — | US | disclosed |
| EP-1387827-B1 | SYNTHESIS OF CYCLOPENTADIENE DERIVATIVES | BASELL POLYOLEFINE GMBH (DE) | 2008-09-24 | — | — | EP | disclosed |
| US-7253292-B2 | Synthesis of cyclopentadiene derivatives | BASELL POLYOLEFINE GMBH (DE) | 2007-08-07 | — | — | US | disclosed |
| US-20040236115-A1 | Synthesis of cyclopentadiene derivatives | EQUISTAR CHEMICALS, LP | 2004-11-25 | — | — | US | disclosed |
| EP-1387827-A2 | SYNTHESIS OF CYCLOPENTADIENE DERIVATIVES | Basell Polyolefine GmbH (DE) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002092564-A2 | SYNTHESIS OF CYCLOPENTADIENE DERIVATIVES | BASELL POLYOLEFINE GMBH (DE) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236115-A1 | Synthesis of cyclopentadiene derivatives | CYCS, DHPS, CBR1 | PNMT 932/4885NOS3 869/4885NOS2 443/4885 |
| US-20080287692-A1 | Synthesis of cyclopentadiene derivatives | CYCS, CYC1, CBR1 | PNMT 2760/4885NOS3 159/4885NOS2 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.